Private Wealth Advisors LLC Has $2.93 Million Stock Position in Delcath Systems, Inc. $DCTH

Private Wealth Advisors LLC increased its stake in Delcath Systems, Inc. (NASDAQ:DCTH) by 85.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 290,481 shares of the company’s stock after acquiring an additional 134,198 shares during the quarter. Private Wealth Advisors LLC owned about 0.82% of Delcath Systems worth $2,934,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Rosalind Advisors Inc. lifted its stake in shares of Delcath Systems by 13.8% in the second quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock worth $44,885,000 after acquiring an additional 400,000 shares during the period. Vanguard Group Inc. lifted its stake in shares of Delcath Systems by 2.9% in the third quarter. Vanguard Group Inc. now owns 1,657,428 shares of the company’s stock worth $17,817,000 after acquiring an additional 46,693 shares during the period. Nantahala Capital Management LLC acquired a new position in shares of Delcath Systems in the third quarter worth approximately $7,164,000. Marshall Wace LLP acquired a new position in shares of Delcath Systems in the second quarter worth approximately $6,572,000. Finally, Divisadero Street Capital Management LP acquired a new position in shares of Delcath Systems in the third quarter worth approximately $5,119,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on DCTH shares. Weiss Ratings raised Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Zacks Research lowered Delcath Systems from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th. BTIG Research dropped their price target on Delcath Systems from $23.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Wall Street Zen lowered Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Evercore set a $27.00 price target on Delcath Systems in a research note on Thursday, February 26th. Five analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $22.50.

Delcath Systems Stock Performance

Shares of DCTH opened at $11.23 on Thursday. Delcath Systems, Inc. has a 52-week low of $8.12 and a 52-week high of $18.19. The business’s 50 day moving average price is $10.24 and its two-hundred day moving average price is $9.87. The firm has a market cap of $387.66 million, a PE ratio of 1,123.00 and a beta of 0.54.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.07. The firm had revenue of $24.99 million for the quarter, compared to analyst estimates of $23.51 million. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%. Research analysts predict that Delcath Systems, Inc. will post -0.88 EPS for the current fiscal year.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.